152 related articles for article (PubMed ID: 37005131)
1. Progressive pulmonary fibrosis in systemic autoimmune diseases. A real life study.
Durán Barata D; Jaureguizar Oriol A; Loarce Martos J; Morell Hita JL; de la Puente Bujidos C; Rigual Bobillo J
Reumatol Clin (Engl Ed); 2023 Apr; 19(4):211-214. PubMed ID: 37005131
[TBL] [Abstract][Full Text] [Related]
2. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
Fischer A; Distler J
Clin Rheumatol; 2019 Oct; 38(10):2673-2681. PubMed ID: 31423560
[TBL] [Abstract][Full Text] [Related]
3. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
7. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
[TBL] [Abstract][Full Text] [Related]
8. Should we use nintedanib as early therapy in patients with SSc-ILD?
Zanatta E; Moccaldi B; Szucs G; Spagnolo P
Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)].
Buschulte K; Hoffmann-Vold AM; Dobrota RD; Höger P; Krause A; Kreuter M
Z Rheumatol; 2021 Oct; 80(8):743-754. PubMed ID: 34505934
[TBL] [Abstract][Full Text] [Related]
10. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
11. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary manifestations and prognosis of a cohort of patients with interstitial lung disease and positive to anti-Th/To autoantibodies.
Mejía M; Ramos-Martínez E; Vázquez-Becerra LE; Fernández-Badillo D; Mateos-Toledo HN; Castillo J; Estrada A; Rojas-Serrano J
Med Clin (Barc); 2024 Apr; 162(8):378-384. PubMed ID: 38290874
[TBL] [Abstract][Full Text] [Related]
13. Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.
Piotrowski WJ; Martusewicz-Boros MM; Białas AJ; Barczyk A; Batko B; Błasińska K; Boros PW; Górska K; Grzanka P; Jassem E; Jastrzębski D; Kaczyńska J; Kowal-Bielecka O; Kucharz E; Kuś J; Kuźnar-Kamińska B; Kwiatkowska B; Langfort R; Lewandowska K; Mackiewicz B; Majewski S; Makowska J; Miłkowska-Dymanowska J; Puścińska E; Siemińska A; Sobiecka M; Soroka-Dąda RA; Szołkowska M; Wiatr E; Ziora D; Śliwiński P
Adv Respir Med; 2022 Oct; 90(5):425-450. PubMed ID: 36285980
[TBL] [Abstract][Full Text] [Related]
14. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
[TBL] [Abstract][Full Text] [Related]
15. Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?
Soskis A; Hallowell R
Respiration; 2021; 100(9):923-932. PubMed ID: 33951665
[TBL] [Abstract][Full Text] [Related]
16. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
[TBL] [Abstract][Full Text] [Related]
17. Management of systemic sclerosis-associated interstitial lung disease.
Roofeh D; Jaafar S; Vummidi D; Khanna D
Curr Opin Rheumatol; 2019 May; 31(3):241-249. PubMed ID: 30870216
[TBL] [Abstract][Full Text] [Related]
18. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
Shumar JN; Chandel A; King CS
J Clin Med; 2021 May; 10(11):. PubMed ID: 34070297
[TBL] [Abstract][Full Text] [Related]
19. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).
Nasser M; Larrieu S; Si-Mohamed S; Ahmad K; Boussel L; Brevet M; Chalabreysse L; Fabre C; Marque S; Revel D; Thivolet-Bejui F; Traclet J; Zeghmar S; Maucort-Boulch D; Cottin V
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 32943410
[TBL] [Abstract][Full Text] [Related]
20. Progressive Disease With Low Survival in Adult Patients With Pulmonary Fibrosis Carrying Surfactant-Related Gene Mutations: An Observational Study.
Klay D; Grutters JC; van der Vis JJ; Platenburg MGJP; Kelder JC; Tromp E; van Moorsel CHM
Chest; 2023 Apr; 163(4):870-880. PubMed ID: 36370864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
